ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Diagnostics

Background:

• TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL), alongside 17p deletion.
• Approximately 5% of untreated CLL patients requiring treatment harbor TP53 mutations without 17p deletion.
• These patients exhibit poor response and reduced survival with standard therapies.

Purpose of the Study:

• To highlight the prognostic significance of TP53 mutations in CLL.
• To advocate for the integration of TP53 mutation testing into routine CLL diagnostics.
• To provide guidance on TP53 mutation detection methods and interpretation.

Main Methods:

• Review of evidence from retrospective analyses and prospective clinical trials.
• Discussion of various TP53 mutation detection assays, recommending Sanger sequencing for certain settings.
• Development of recommendations for standard operating procedures, quality control, reporting, and interpretation.

Main Results:

• TP53-mutated CLL patients without 17p deletion show inferior outcomes with standard treatments.
• Sanger sequencing of TP53 exons 4-9 is a viable method for mutation detection.
• Specific management strategies, including allogeneic stem cell transplantation and clinical trials, are suggested for these patients.

Conclusions:

• TP53 mutation testing should be incorporated into the diagnostic workup for CLL patients.
• Patients with TP53 mutations may benefit from intensified treatment approaches, including stem cell transplantation or novel agents.
• Further research and clinical trials are essential for optimizing treatment for TP53-mutated CLL.